At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 482 enrolled
Drug / intervention
Rilpivirinedrug
Likely dose
Rilpivirine 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Trial With TMC278 25 mg q.d. in Combination With a Background Regimen Containing 2 N(t)RTI's in HIV-1 Infected Subjects Who Participated in TMC278 Clinical Trials and Were Still Benefitting From Treatment With TMC278
In Brief
A Phase 3 clinical trial evaluating Rilpivirine for HIV-1 Infection. Completed, enrolled 482 participants across 98 sites in 21 countries.
Detailed Summary
The purpose of the study is to provide continued access to TMC278 in HIV-1 infected patients who were randomized and treated with TMC278 in the Phase IIb or Phase III trials.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1 Infection
CountriesArgentina, Australia, Austria, Belgium, Canada, Chile, China, Denmark, France, Germany, Netherlands, Puerto Rico, Romania, Russia, South Africa, Spain, Sweden, Taiwan, Thailand, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2010
Enrollment StartFeb 2011
Primary CompletionFeb 2020
TodayJul 2026
First PostedDec 24, 2010
Enrollment StartFeb 1, 2011
Primary CompletionFeb 1, 2020
TodayJul 2, 2026
Enrollment to primary: 9 yearsPosted 15.5 years ago
Interventions
Rilpivirinedrug
25 mg once daily